Madrigal Pharmaceuticals’ Rezdiffra Shows Strong Market Growth and Positive Outlook, Justifying Buy Rating
Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a price target ...
Brokerages Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Price Target at $347.33
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the stock, Marketbeat.com ...
Y-mAbs Therapeutics appoints Gentilcore as SVP, head of DANYELZA unit
Y-mAbs Therapeutics (YMAB) announced the appointment of Doug Gentilcore as Senior Vice President SVP, Head of DANYELZA Business Unit. Prior to ...
pharmaphorum20h
Pharma’s climate change vulnerability and opportunity
As one of the world’s biggest contributors to climate change, pharma is morally obliged to adapt its processes and operations – and doing so will open up new opportunities for growth.
Indiatimes20h
Sun Pharmaceutical Industries Share Price
Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 4,38,202.54 Crore) operating in Pharmaceuticals sector. Sun Pharmaceutical ...